 |
Telephone: +47 23073015
E-mail: b.bogen@labmed.uio.no
FAX: +47 23 073510 /
+47 23 073822
Selected recent publications
2006
Fredriksen
AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of
idiotypic tumor antigen by targeting novel fusion proteins to antigen
presenting cells. Mol Ther. 2006 Apr;13(4):776-85. Epub 2006 Jan 18
Husebye H, Halaas
O, Stenmark H, Tunheim G, Sandanger O, Bogen B, Brech A, Latz E,
Espevik T. Endocytic pathways regulate Toll-like receptor 4 signaling
and link innate andadaptive immunity. EMBO J. 2006 Feb 22;25(4):683-92. Epub 2006 Feb 9.
2005
Corthay
A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G,
Bogen B. Primary Antitumor Immune Response Mediated by CD4(+) T Cells.
Immunity. 2005 Mar;22(3):371-83.
Munthe
LA, Corthay A, Os A, Zangani M, Bogen B. Systemic autoimmune disease
caused by autoreactive B cells that receive chronic help from Ig v
region-specific T cells. J Immunol. 2005 Aug 15;175(4):2391-400.
Schjetne KW, Thommesen JE, Fredriksen AB, Lunde E, Sandlie I, Bogen B.
Induction
of central T cell tolerance: recombinant antibodies deliver peptides
for deletion of antigen-specific (CD4+)8+ thymocytes. Eur. J. Immunol.
2005 2005 Nov;35(11):3142-52
2004
Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B.
Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther. 2004 Mar;9(3):328-36.
Munthe,
L A., Os, A., Zangani, M, Bogen, B. MHC-Restricted Ig V Region-Driven
T-B Lymphocyte Collaboration: B Cell Receptor Ligation Facilitates
Switch to IgG Production.
J .Immunol 2004 Jun 15;172(12):7476-84.
2003
Lundin
KU, Hofgaard PO, Omholt H, Munthe, LA, Corthay A, Bogen B (2003).
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell
lymphoma in the absence of anti-idiotypic antibodies. Blood
102:605-612, 2003
Schjetne, K.W., Thompson K.M., Fleckenstein
B., Aarvak T., Flo T.H., Iversen J.G:, Espevik T., Bogen B (2003).
Cutting edge: Link between innate and adaptive immunity: Toll like
receptor 2 (TLR 2) captures antigen for MHC class II presentation to
CD4+ T cells. J. Immunol. 171: 32–36, 2003.
Schjetne, K
W., Gundersen, H.T., Iversen, J.-G., Thompson, K. M., Bogen
B. Antibody-mediated delivery of antigen to chemokine receptors
on APC results in enhanced CD4+ T cell responses. Eur J Immunol. 2003
Nov;33(11):3101-8.
2002
Lunde
E., Western K.H., Rasmussen I B., Sandlie I, Bogen B (2002). Efficient
delivery of T-cell epitopes to APC by use of MHC class II-specific
antibodies. J. Immunol. 168:2154-2162
Karoline W. Schjetne,
Keith M. Thompson, Tanja Aarvak, Burkhard Fleckenstein, Ludvig M.
Sollid, Bjarne Bogen (2002). A mouse Ck-specific T cell clone indicates
that DC-SIGN is an efficient target for antibody-mediated delivery of T
cell epitopes for MHC class II presentation. Int. Immunol 14:
1423-1430
2001
Rasmussen,I.B.,
E.Lunde, T.E.Michaelsen, B.Bogen, and I.Sandlie. 2001. The principle of
delivery of T cell epitopes to antigen-presenting cells applied to peptides
from influenza virus, ovalbumin, and hen egg lysozyme: Implications for
peptide vaccination. Proc.Natl.Acad.Sci.U.S.A 98:10296-10301.
McAdam,S.N.,
B.Fleckenstein, I.B.Rasmussen, D.G.Schmid, I.Sandlie, B.Bogen, N.J.Viner,
and L.M.Sollid. 2001. T cell recognition of the dominant I-A(k)-restricted
hen egg lysozyme epitope: critical role for asparagine deamidation. J.Exp.Med.
193:1239-1246.
Dembic,Z.,
J.A.Rottingen, J.Dellacasagrande, K.Schenck, and B.Bogen. 2001. Phagocytic
dendritic cells from myelomas activate tumor-specific T cells at a single
cell level. Blood 97:2808-2814.
2000
Dembic,Z.,
K.Schenck, and B.Bogen. 2000. Dendritic cells purified from myeloma are
primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Proc.Natl.Acad.Sci.U.S.A 97:2697-2702.
1999
Munthe,L.A.,
J.A.Kyte, and B.Bogen. 1999. Resting small B cells present endogenous
immunoglobulin variable-region determinants to idiotope-specific CD4(+)
T cells in vivo. Eur.J.Immunol. 29:4043-4052.
Djerbi,M.,
V.Screpanti, A.I.Catrina, B.Bogen, P.Biberfeld, and A.Grandien. 1999.
The inhibitor of death receptor signaling, FLICE-inhibitory protein defines
a new class of tumor progression factors. J.Exp.Med. 190:1025-1032.
Lunde,E.,
L.A.Munthe, A.Vabo, I.Sandlie, and B.Bogen. 1999. Antibodies engineered
with IgD specificity efficiently deliver integrated T-cell epitopes for
antigen presentation by B cells. Nat.Biotechnol. 17:670-675.